ArticleArchives of dermatological research2025
Identifying transcriptomic predictors of brodalumab response in psoriasis using CART analysis.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials.Dermatology and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine is a topic of growing interest in psoriasis. Many novel biologics are now available to clinicians and identifying who will be a responder or non-responder to a given biologic prior to treatment is an exciting area of inquiry with strong potential clinical utility. In the present study, we use an interpretable classification and regression tree (CART) model to predict week 12 PASI75 and PASI90 response to brodalumab treatment based on clinical variables and transcriptomic data from lesional biopsy tissue samples. We identify KRT16 normalized RNA expression levels and BMI as pre-treatment predictors of a PASI75 response and FERMT1, HLA_DQA1, TMPRSS11D, and S100P normalized RNA expression levels as pre-treatment predictors of a PASI90 response. The CART models demonstrated strong AUC values for the PASI75 (0.90) and PASI90 (0.88) analyses. Taken together, focused transcriptomics has the potential to be used clinically for the pre-treatment prediction of treatment response.
Indexed as
Identifiers
40140063What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.